Thromb Haemost 1998; 79(03): 614-619
DOI: 10.1055/s-0037-1614955
Review Articles
Schattauer GmbH

Inhibition of Rat Platelet Aggregation by Mycalolide-B, a Novel Inhibitor of Actin Polymerization with a Different Mechanism of Action from Cytochalasin-D

Atsuhiro Sugidachi
1   From the Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Department of Veterinary Pharmacology
,
Fumitoshi Asai
1   From the Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Department of Veterinary Pharmacology
,
Shinya Saito
1   From the Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Department of Veterinary Pharmacology
,
Hiroshi Ozaki
1   From the Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Department of Veterinary Pharmacology
,
Nobuhiro Fusetani
2   Department of Marine Biochemistry, Graduate School of Agriculture and Life Sciences, The University of Tokyo, Japan
,
Hideaki Karaki
1   From the Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Department of Veterinary Pharmacology
,
Hiroyuki Koike
1   From the Pharmacology and Molecular Biology Research Laboratories, Sankyo Co., Ltd., Department of Veterinary Pharmacology
› Institutsangaben
Weitere Informationen

Publikationsverlauf

Received 29. Mai 1997

Accepted after resubmission 09. November 1997

Publikationsdatum:
07. Dezember 2017 (online)

Summary

In vitro effects of mycalolide-B (MB), isolated from marine sponge, were investigated with regard to the activation of rat platelets. Collagen-induced platelet aggregation in platelet-rich plasma (PRP) was slightly but significantly potentiated by lower concentrations of MB (0.3 and 1 μM) but was inhibited by higher concentrations (3 and 10 μM). ADP-induced platelet aggregation in PRP was also significantly prevented by MB (1-10 μM). Potentiation of ADP-induced aggregation by MB (0.3 μM) was hardly observed. G-actin contents, determined by DNase I inhibition assay, were increased in resting washed platelets incubated with MB (3 μM). In contrast, cytochalasin-D (CD) at 3 μM slightly reduced G-actin contents in resting platelets. After platelet aggregation with collagen (3 μg/ml) or ADP (10 μM), G-actin contents in platelets were reduced, indicating de novo actin polymerization. MB (3 μM) and CD (3 μM) abolished both ADP (10 μM)- and collagen (3 μg/ml)-induced platelet aggregation and actin polymerization in washed platelets. MB (1-10 μM) had no effects on intracellular Ca2+ concentrations in ADP (10 μM)-stimulated platelets. [125I]-fibrinogen binding to activated platelets with ADP (10 μM) was inhibited by MB (0.3-3 μM) in a concentration-dependent manner. Thrombin-induced platelet-fibrin clot retraction was inhibited by MB (1 and 10 μM). These results suggest that MB inhibits platelet activation by interfering with actin polymerization through a different mechanism of action from CD. MB may be a useful tool for studying the role of actin polymerization in various cells.

 
  • References

  • 1 Fox JE, Phillips DR. Polymerization and organization of actin filaments within platelets. Semin Hematol 1983; 20: 243-60.
  • 2 Heptinstall S, Glenn J, Spangenberg P. Changes in G-actin after platelet activation in platelet rich plasma. Thromb Haemost 1992; 68: 727-30.
  • 3 Cooper JA. Effects of cytochalasin and phalloidin on actin. J Cell Biol 1987; 105: 1473-8.
  • 4 Franki N, Ding G, Gao Y, Hays RM. Effect of cytochalasin D on the actin cytoskeleton of the toad bladder epithelial cell. Am J Physiol 1992; 263: C995-1000.
  • 5 Wright G, Hurn E. Cytochalasin inhibition of slow tension increase in rat aortic rings. Am J Physiol 1994; 267: H1437-46.
  • 6 Fox JE, Phillips DR. Inhibition of actin polymerization in blood platelets by cytochalasins. Nature 1981; 292: 650-2.
  • 7 Tellam R, Frieden C. Cytochalasin D and platelet gelsolin accelerate actin polymer formation. A model for regulation of the extent of actin polymer formation in vivo. Biochemistry 1982; 21: 3207-14.
  • 8 Haslam RJ, Davidson MM, McClenaghan MD. Cytochalasin B the blood platelet release reaction and cyclic GMP. Nature 1975; 253: 455-7.
  • 9 Peerschke EI. Observations on the effects of cytochalasin B and cytochalasin D on ADP- and chymotrypsin-treated platelets. Proc Soc Exp Biol Med 1984; 175: 109-15.
  • 10 Oda A, Daley JF, Cabral C, Kang JH, Smith M, Salzman EW. Heterogeneity in filamentous actin content among individual human blood platelets. Blood 1992; 79: 920-7.
  • 11 Lefebvre P, White JG, Krumwiede MD, Cohen I. Role of actin in platelet function. Eur J Cell Biol 1993; 62: 194-204.
  • 12 Heptinstall S, Glenn JR, Losche W, Spangenberg P. ADP-induced platelet aggregation and actin polymerization. Involvement of GpIIb/IIIa and the effect of Mg2+ . Semin Thromb Hemost 1995; 21: 137-45.
  • 13 Asazuma N, Yatomi Y, Ozaki Y, Qi R, Kuroda K, Satoh K, Kume S. Protein-tyrosine phosphorylation and p72syk activation in human platelets stimulated with collagen is dependent upon glycoprotein Ia/IIa and actin polymerization. Thromb Haemost 1996; 75: 648-54.
  • 14 Fusetani N, Yasumuro K, Matsunaga S, Hashimoto K. Mycalolide A-C hybrid macrolide of ulapualides and halichondramide, from a sponge of the genous mycale. Tetrahedron Lett 1989; 30: 2809-12.
  • 15 Hori M, Saito S, Shin YZ, Ozaki H, Fusetani N, Karaki H. Mycalolide-B, a novel and specific inhibitor of actomyosin ATPase isolated from marine sponge. FEBS Lett 1993; 322: 151-4.
  • 16 Saito S, Watabe S, Ozaki H, Fusetani N, Karaki H, Mycalolide B. a novel actin depolymerizing agent. J Biol Chem 1994; 269: 29710-4.
  • 17 Saito S, Watabe S, Ozaki H, Kigoshi H, Yamada K, Fusetani N, Karaki H. Novel actin depolymerizing maclolide Aplyronine A. J Biochem 1996; 120: 552-5.
  • 18 Sugidachi A, Asai F, Oshima T, Koike H. Intracellular Ca2+ mobilization and aggregatory response to ADP and thrombin in aged rat platelets. Platelets 1995; 6: 388-93.
  • 19 Sugidachi A, Breiter N, Ogawa T, Asai F, Koike H. In vitro effects of aprosulate sodium, a novel anticoagulant, on platelet activation: Possible mechanism for antiplatelet action. Thromb Haemost 1996; 76: 786-90.
  • 20 Holme TC, Kellie S, Wyke JA, Crawford N. Effect of transformation by Rous sarcoma virus on the character and distribution of actin in Rat-1 fibroblasts: A biochemical and microscopical study. Br J Cancer 1986; 53: 465-76.
  • 21 Sugidachi A, Asai F, Oshima T, Koike H. Age-associated changes in intracellular Ca2+ mobilization and basal pH level in rat platelets. Platelets 1993; 4: 91-5.
  • 22 Grynkiewicz G, Poenie M, Tsien RY. A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-50.
  • 23 Di Minno G, Cerbone AM, Mattioli PL, Turco S, Iovine C, Mancini M. Functionally thrombasthenic state in normal platelets following the administration of ticlopidine. J Clin Invest 1985; 75: 328-38.
  • 24 Cattaneo M, Lecchi A, Randi AM, McGregor JL, Mannucci PM. Identification of a new congenital defect of platelet function characterized by severe impairment of platelet responses to adenosine diphosphate. Blood 1992; 80: 2787-96.
  • 25 Dwyer SD, Meyers KM. Anesthetics and anticoagulants used in the preparation of rat platelet rich plasma alter rat platelet aggregation. Thromb Res 1986; 42: 139-51.
  • 26 Takahashi O. Some properties of rat platelet aggregation and effects of butylated hydroxytoluene, warfarin and aspirin. Food Chem Toxicol 1991; 29: 173-83.
  • 27 Jung CY, Rampal AL. Cytochalasin B binding sites and glucose transport carrier in human erythrocyte ghosts. J Biol Chem 1977; 252: 5456-63.
  • 28 Brenner SL, Korn ED. The effects of cytochalasins on actin polymerization and actin ATPase provide insights into the mechanism of polymerization. J Biol Chem 1980; 255: 841-4.
  • 29 van Deurs B, Behnke O. Membrane structure of nonactivated and activated human blood platelets as revealed by freeze-fracture: evidence for particle redistribution during platelet contraction. J Cell Biol 1980; 87: 209-18.
  • 30 Glenn JR, Spangenberg P, Heptinstall S. Platelet-platelet contact and thromboxane A2 contribute to actin polymerization in platelets stimulated with ADP. Platelets 1994; 5: 84-9.
  • 31 Addo JB, Bray PF, Grigoryev D, Faraday N, Goldschmidt-Clermont PJ. Surface recruitment but not activation of integrin αIIbβ3 (GPIIb-IIIa) requires a functional actin cytoskeleton. Arterioscler Thromb Vasc Biol 1995; 15: 1466-73.
  • 32 Gachet C, Cazenave JP. ADP induced blood platelet activation: a review. Nouv Rev Fr Hematol 1991; 33: 347-58.
  • 33 Heemskerk JW, Sage SO. Calcium signaling in platelets and other cells. Platelets 1994; 5: 295-316.
  • 34 Ariyoshi H, Salzman EW. Association of localized Ca2+ gradients with redistribution of glycoprotein IIb-IIIa and F-actin in activated human blood platelets. Arterioscler Thromb Vasc Biol 1996; 16: 230-5.
  • 35 Phillips DR, Jennings LK, Edwards HH. Identification of membrane proteins mediating the interaction of human platelets. J Cell Biol 1980; 86: 77-86.
  • 36 Fox JE. Identification of actin-binding protein as the protein linking the membrane skeleton to glycoproteins on platelet plasma membranes. J Biol Chem 1985; 260: 11970-7.
  • 37 Suzuki H, Tanoue K, Yamazaki H. Morphological evidence for the association of plasma membrane glycoprotein IIb/IIIa with the membrane skeleton in human platelets. Histochemistry 1991; 96: 31-9.
  • 38 Gartner TK, Ogilvie ML. Peptides and monoclonal antibodies which bind to platelet glycoproteins IIb and/or IIIa inhibit clot retraction. Thromb Res 1988; 49: 43-53.
  • 39 Cohen I, Burk DL, White JG. The effect of peptides and monoclonal antibodies that bind to platelet glycoprotein IIb-IIIa complex on the development of clot tension. Blood 1989; 73: 1880-7.
  • 40 Fournier DJ, Kabral A, Castaldi PA, Berndt MC. A variant of Glanzmann’s thrombasthenia characterized by abnormal glycoprotein IIb/IIIa complex formation. Thromb Haemost 1989; 62: 977-83.